Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Hepatotoxicity of New Oral Anticoagulants

https://doi.org/10.20996/1819-6446-2018-14-4-621-628

Full Text:

Abstract

Aim. To summarize and systematize the information published in open sources on the development of various manifestations of liver damage in the use of the new oral anticoagulants (NOAC) for the registered indications and to analyze the published clinical cases of drug induced liver injury (DILI) development.

Material and methods. Search queries for keywords were made in the PubMed (MEDLINE), Scopus, Elibrary and Kiberleninka databases. The search query was composed of the name of the medicinal product (international non-proprietary and commercial name) or the common name of the group and words describing the different variants of the liver damage.

Results. As a result of the search 1497 articles were found. Duplicate articles, articles that do not match the review topic, and articles whose full-text version is not available were removed from the search results. Articles that do not describe specific clinical cases have also been excluded. The review includes 14 articles, published from 2007 to March 2018 in Russian and English and one article in French describing clinical cases of different types of hepatotoxicity in the application of NOAC.

Conclusions. Published clinical cases suggest that NOAC cause undesirable phenomena such as hepatotoxicity, the mechanism and frequency of which remain unclear.

About the Authors

A. R. Kasimova
Pavlov First Saint Petersburg State Medical University; Russian Scientific Research Institute of Traumatology and Orthopedics named after R.R. Vreden
Russian Federation

Alina R. Kasimova – Post-Graduate Student, Chair of Clinical Pharmacology and Evidence-Based Medicine, Pavlov First Saint Petersburg State Medical University; Clinical Pharmacologist, Department of Clinical Pharmacology, Russian Scientific Research Institute of Traumatology and Orthopedics named after R.R. Vreden 

L'va Tolstogo ul. 6-8, Saint Petersburg, 197022; Academica Baykova ul. 8, Saint Petersburg, 195427



A. V. Philippova (Guryanova)
Pavlov First Saint Petersburg State Medical University
Russian Federation

Anastasia V. Philippova (Guryanova) – Post-Graduate Student, Chair of Clinical Pharmacology and Evidence-Based Medicine

L'va Tolstogo ul. 6-8, Saint Petersburg, 197022



A. S. Kolbin
Pavlov First Saint Petersburg State Medical University
Russian Federation

Alexey S. Kolbin – MD, PhD, Professor, Head of Chair of Clinical Pharmacology and Evidence-Based Medicine

L'va Tolstogo ul. 6-8, Saint Petersburg, 197022



References

1. Kvasnicka T., Malikova I., Zenahlikova Z., et al. Rivaroxaban metabolism, pharmacologic properties and drug interactions. Curr Drug Metab. 2017;18(7):636-42. doi: 10.2174/1389200218666170518165443.

2. Lassen M.R., Raskob G.E., Gallus A., et al. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Eng J Med. 2009;361:594-604. doi: 10.1056/NEJMoa1006885.

3. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47(5):285-295. doi: 10.2165/00003088200847050-00001.

4. Tajiri K., Shimizu Y. Practical guidelines for diagnosis and early management of druginduced liver injury. World J Gastroenterol. 2008;14(44):6774-85. doi: 10.3748/wjg.14.6774.

5. Goldberg D.S., Forde K.A., Carbonari D.M., et al. Population-representative incidence of drug-induced acute liver failure based on an analysis of an integrated health care system. Gastroenterology. 2015;148:1353-61. doi: 10.1053/j.gastro.2015.02.050.

6. Björnsson E.S., Bergmann O.M., Björnsson H.K., et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology. 2013;144:1419-25. doi: 10.1053/j.gastro.2013.02.006.

7. Wysowski D.K., Swartz L. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. Arch Intern Med. 2005;165:13639. doi: 10.1001/archinte.165.12.1363.

8. Lauschke V., Ingelman-Sundberg M. The importance of patient-specific factors for hepatic drug response and toxicity. Int J Mol Sci. 2016;17:1714. doi: 10.3390/ijms17101714.

9. Kaplowitz N. Idiosyncratic drug hepatotoxicity. Nat Rev Drug Discov. 2005; 4(6):489-99. doi: 10.1038/nrd1750.

10. Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol. 1990;11(2):272-6. doi: 10.1016/0168-8278(90)90124-A.

11. Aithal G.P., Watkins P.B., Andrade R.J., et al. Case definition and phenotype standardization in druginduced liver injury. Clin Pharmacol Ther. 2011;89(6):806-15. doi: 10.1038/clpt.2011.58.

12. Tajiri K., Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury. World J Gastroenterol. 2008;14(44):6774-85. doi: 10.3748/wjg.14.6774.

13. Harder S., Graff J. Novel oral anticoagulants: clinical pharmacology, indications and practical considerations. Eur J Clin Pharmacol. 2013; 69:1617-33. doi: 10.1007/s00228-013-1510-z.

14. Lee W.M., Larrey D., Olsson R., et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf. 2005; 28:351-70. doi: 10.1007/978-3-642-00663-0_13.

15. Keisu M., Andersson T. Drug-induced liver injury in humans: the case of ximelagatran. Handb Exp Pharmacol. 2010; 196:407-18. doi: 10.1007/978-3-642-00663-0_13.

16. Xarelto. Summary of product characteristics. [cited by August 23, 2018. Available from: https://www.xarelto.com/en/congress-materials/pdf/SPC_Oct_2017.pdf.

17. Watkins P.B., Desai M., Berkowitz S.D., et al. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf. 2011;34:243-52. doi: 10.2165/11586600000000000-00000.

18. Licata A., Puccia F., Lombardo V., et al. Rivaroxaban-induced hepatotoxicity: review of the literature and report of new cases. Eur J Gastroenterol Hepatol. 2018;30(2):226-232. doi: 10.1097/MEG.0000000000001030.

19. Glenn K., Chen P., Musleh M., et al. A Rare Case of Rivaroxaban Causing Delayed Symptomatic Hepatocellular Injury and Hyperbilirubinemia. Case Rep Gastrointest Med. 2017;2017:5678187. doi: 10.1155/2017/5678187.

20. Aslan A.N., Sari C., Baştuğ S., et al. Severe jaundice due to intrahepatic cholestasis after initiating anticoagulation with rivaroxaban. Blood Coagul Fibrinolysis. 2016;27(2):226-7. doi: 10.1097/MBC.0000000000000442.

21. Lee W.M., Larrey D., Olsson R., et al. Hepatic findings in long-term clinical trials of ximelagatran. Drug Saf. 2005; 28:351-70. doi: 10.1016/j.ijcard.2015.11.147.

22. Cordeanu M., Lambert A., Gaertner S., et al. Apixaban-induced hepatotoxicity. Int J Cardiol. 2016;1;204:4-5. doi: 10.1136/bcr-2016-216744.

23. Clarke S.A., Alsaad A.A., Mack A., et al. Apixaban-induced liver injury. BMJ Case Rep. 2016. doi: 10.1136/bcr-2016-216744.

24. Pradaxa.Summaryofproductcharacteristics.[citedbyAugust23,2018.Availablefrom:http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf.

25. Rochwerg B., Xenodemetropoulos T., Crowther M., et al. Dabigatran-induced acute hepatitis. Clin Appl Thromb Hemost. 2012;18(5):549-50. doi: 10.1177/1076029611435840.

26. Fulcrand J., Lerooy A., Giraud J., et al. le réseau des Centres régionaux de Pharmacovigilance. [Cytolysis in an elderly patient treated with dabigatran etexilate. Therapie. 2013 Sep-Oct;68(5):3324. doi: 10.2515/therapie/2013053.

27. Caldeira D., Barra M., Santos A.T., et al. Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis. Heart. 2014;100 (7):550-6. doi: 10.2515/therapie/2013053.

28. Liakoni E., Rätz Bravo A.E., Krähenbühl S. Hepatotoxicity of New Oral Anticoagulants (NOACs). Drug Saf. 2015;38 (8):711-20. doi: 10.1136/heartjnl-2013-305288.

29. Raschi E. Poluzzi E, Koci A, et al. Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system. Br J Clin Pharmacol. 2015;80(2):285-93. doi: 10.1111/bcp.12611.


For citation:


Kasimova A.R., Philippova (Guryanova) A.V., Kolbin A.S. Hepatotoxicity of New Oral Anticoagulants. Rational Pharmacotherapy in Cardiology. 2018;14(4):621-628. (In Russ.) https://doi.org/10.20996/1819-6446-2018-14-4-621-628

Views: 226


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)